Page 142 - Read Online
P. 142

Akinci et al. Vessel Plus 2021;5:56  https://dx.doi.org/10.20517/2574-1209.2021.20                                                                                    Page 15 of 20


                              Table 2. Pharmacological characteristics of intravenous and transdermal antihypertensive agents used in acute blood pressure management in intracerebral hemorrhage patients in clinical trials

                                                                                                                                                                           Platelet
                              Agent                    Mechanism of action              Intravenous dose             Onset         Half-life     CBF ICP Autoregulation               Trial name
                                                                                                                                                                           activity
                              Labetalol [13,17,77,78]  α , β , and β -receptor blocker  5-20 mg bolus every 15 min   1-2 min       9 min         …    …    …               -          INTERACT  [38] , INTERACT-2 [49] ,
                                                        1
                                                           1
                                                                 2
                                                                                                                                                                                      ATACH-2  [48] , Koch et al. [52]
                              Metoprolol [77,78]       Selective β -receptor blocker    20-80 mg every 10 min        5-10 min      3-7 h         …    …    …               -          INTERACT, INTERACT-2  [38,49]
                                                                1
                                                                                                                                                                                                 [49]
                              Esmolol [17]             Selective β -receptor blocker    250 μg/kg bolus followed by 25   1-2 min   9 min         …    …    …               +          INTERACT-2
                                                                1
                                                                                        to 300 μg/kg/min
                              Urapidil [79,80]         Peripheral α1-receptor antagonist   12.5-25 mg bolus followed by 5-  3-5 min  2-4.8 h     …    …    …               -          INTERACT, INTERACT-2,
                                                       and central serotonin 1A receptor   40 mg/h infusion                                                                           ATACH-2  [38,48,49]
                                                       stimulator
                              Phentolamine [81,82]     Peripheral nonselective α-receptor   1-5 mg bolus every 5-10 min  1-2 min   19 min        …    …    ...             -          INTERACT, INTERACT-2  [38,49]
                                                       antagonist
                              Clonidine [83]           Central α -receptor agonist      1.2-7.2 μg/min               5-10 min      12 h          …    …    …               …          INTERACT-2 [49]
                                                               2
                              Sodium nitroprusside [17,93]  Mixed arterial/venous vasodilator   0.25-4 μg/kg/min     1-2 min       < 10 min      ++   ++   -               -          INTERACT  [38] , INTERACT-2 [49] ,
                                                       (nitric oxide donor)                                                                                                           Koch et al. [52]
                              Nitroglycerine [17]      Mixed arterial/venous vasodilator   20-400 μg/min             1-2 min       3-5 min       +    …    …               -          INTERACT  [38] , INTERACT-2 [49] ,
                                                       (nitric oxide donor)                                                                                                           Gong et al. [66]
                              Transdermal glyceryl     Mixed arterial/venous vasodilator   0.2 mg/h, 5 mg/24 h       15-30 min     Up to 24 h    …    …    …               …          INTERACT, ENOS, RIGHT,
                                                                                                                                                                                              [38,64,72,73]
                              trinitrate [64,84-87]    (nitric oxide donor)                                                                                                           RIGHT-2
                              Nicardipine [13,88]      Calcium channel blocker          5-15 mg/h                    5-10 min      2-4 h         +    …    -               -          INTERACT  [38] , ATACH [48] ,
                                                                                                                                                                                      INTERACT-2 [49] , ATACH-2 [54] ,
                                                                                                                                                                                               [52]
                                                                                                                                                                                      Koch et al.
                              Diltiazem [88,89]        Calcium channel blocker          0.25 mg/kg bolus followed by 5- 2-7 min    3.4 h         …    …    …               -          ATACH-2  [54]
                                                                                        15 mg/h infusion

                              Hydralazine [17]         Arterial vasodilator             5-20 mg bolus every 15 min   5-20 min      2-8 h         ++   ++   -               -          INTERACT, ICH ADAPT,
                                                                                                                                                                                      INTERACT-2 [38,49,59]
                              Enalapril [17]           ACE inhibitor                    1.25-5 mg every 6 h          15-30 min     11 h          …    …    ++              -
                                                                                                                                                                                                            [38,49]
                              Diuretics (furosemide,   Inhibits reabsorption of Na/Cl in the  Furosemide: 20-40 mg bolus   Furosemide:   Furosemide:   …/… …/… …/…         -/-        INTERACT, INTERACT-2
                              bumetanide) [90-92]      ascending loop of Henle          followed by 10-40 mg/h       5 min         30-60 min
                                                                                        Bumetanide: 0.5-1 mg/dose up to  Bumetanide:   Bumetanide: 1-
                                                                                        2 times a day followed by    2-3 min       1.5 h
                                                                                        0.5-2 mg/h

                              ACE: Angiotensin-converting enzyme; CBF: cerebral blood flow; ICP: intracranial pressure; +: increase or favorable effects; ++: subctantial increase or favorable effects; -: decrease or negative effects; …: no
                              documented direct effect.
   137   138   139   140   141   142   143   144   145   146   147